Back

Multimodal single-cell and spatial profiling reveals altered T cell-mediated immunity and B-cell follicular architecture in non-metastatic lymph nodes of patients with aggressive non-small cell lung cancer

Xi, Z. H.; Koga, Y.; McDermott, S.; Kane, E.; Pfefferkorn, R.; Billatos, E.; Hosking, P. R.; Beane, J.; Burks, E. J.; Mazzilli, S. A.; Suzuki, K.; Campbell, J. D.

2026-01-18 oncology
10.64898/2026.01.12.25343268 medRxiv
Show abstract

Regional lymph nodes (LNs) in the thoracic cavity serve as essential immunological hubs that coordinate humoral and cell-mediated responses against the development and progression of non-small cell lung cancer (NSCLC). To investigate immune dysregulation in the non-metastatic regional LNs of patients with aggressive NSCLC, we performed multimodal profiling on 36 LNs from 11 patients undergoing curative-intent resection including CITE-seq, scRNA-seq, and Imaging Mass Cytometry (IMC). Regional N1 LNs from patients with more aggressive disease (stage IB-IIIA) exhibited a significant enrichment of dysfunctional CD8 T cells and regulatory T cells (Tregs) compared to N2 LNs and LNs from patients with less aggressive disease (stage IA). These immune subsets were spatially co-localized with mature regulatory dendritic cells (mregDCs; CD1c, TIM3, LAMP3), forming an immunosuppressive niche uniquely enriched in the N1 LNs of higher-stage patients. Concurrently, higher-stage N1 LNs contained larger number of "decorticated" B-cell follicles characterized by decreased encapsulation of the mantle zone layer surrounding the germinal centers. This mantle zone disorganization was associated with increased spatial niches involving Tregs, CD68+ CD163 TIM3 Macrophages, CD163 TIM3dim Monocytic-Myeloid Derived Suppressor Cells (M-MDSC), plasma B cells, and a decrease in spatial niches involving CD4 T helper cells and fibroblastic reticular cells (FRCs). Together, our findings reveal parallel alterations in humoral and cell-mediated immunity within the regional LNs of patients with aggressive NSCLC.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Cancer Cell
38 papers in training set
Top 0.1%
34.1%
2
Nature Communications
4913 papers in training set
Top 13%
13.1%
3
Cell Reports
1338 papers in training set
Top 6%
6.6%
50% of probability mass above
4
Cancer Discovery
61 papers in training set
Top 0.3%
5.0%
5
eLife
5422 papers in training set
Top 19%
4.5%
6
Journal of Clinical Investigation
164 papers in training set
Top 0.7%
4.1%
7
iScience
1063 papers in training set
Top 9%
2.1%
8
Nature Cancer
35 papers in training set
Top 0.7%
1.8%
9
Science
429 papers in training set
Top 14%
1.7%
10
Clinical Cancer Research
58 papers in training set
Top 1%
1.4%
11
Signal Transduction and Targeted Therapy
29 papers in training set
Top 0.9%
1.3%
12
Cell
370 papers in training set
Top 14%
1.3%
13
Immunity
58 papers in training set
Top 3%
1.3%
14
Cancer Research
116 papers in training set
Top 3%
1.0%
15
Cell Genomics
162 papers in training set
Top 5%
1.0%
16
Cell Reports Medicine
140 papers in training set
Top 6%
0.9%
17
Journal of Hematology & Oncology
10 papers in training set
Top 0.2%
0.8%
18
Molecular Cancer
14 papers in training set
Top 0.8%
0.8%
19
Science Immunology
81 papers in training set
Top 2%
0.8%
20
Nature Genetics
240 papers in training set
Top 7%
0.8%
21
Frontiers in Immunology
586 papers in training set
Top 7%
0.8%
22
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 44%
0.8%
23
Nature
575 papers in training set
Top 15%
0.8%
24
Cancer Immunology Research
34 papers in training set
Top 0.5%
0.7%
25
Oncogene
76 papers in training set
Top 2%
0.7%
26
Journal of Experimental Medicine
106 papers in training set
Top 4%
0.7%
27
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.8%
0.7%
28
Gastroenterology
40 papers in training set
Top 2%
0.7%
29
Cancer Letters
32 papers in training set
Top 1%
0.5%
30
Protein & Cell
25 papers in training set
Top 3%
0.5%